Optimising Screening for Early Disease Detection in Familial Pulmonary Fibrosis

Last updated: May 4, 2022
Sponsor: St. Antonius Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Pulmonary Fibrosis

Cystic Fibrosis

Lung Injury

Treatment

N/A

Clinical Study ID

NCT05367349
NL75303.100.20
  • Ages > 18
  • All Genders

Study Summary

In this study the prognostic value of the current screening parameters for familial pulmonary fibrosis (FPF) will be investigated by looking at the screenings of 200 first-degree relatives of patients with FPF.

Also insight in the natural history of early FPF, and the necessary interval between screenings visits will be investigated.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Asymptomatic first-degree relative of patients with familial pulmonary fibrosis (FPF)

Exclusion

Exclusion Criteria:

  • A previous diagnosis of interstitial lung disease (ILD)
  • Minors (aged <18 years)
  • Pregnant Note: woman who are pregnant at the start of the study or at the time of the HRCT are notallowed to participate. If a participant gets pregnant at a later stage during the study,she will not be excluded from the study. To be able to account for a potential effect ofpregnancy during data analysis, female participants can be asked if they are pregnant atevery visit.

Study Design

Total Participants: 200
Study Start date:
June 16, 2021
Estimated Completion Date:
September 01, 2025

Study Description

Familial pulmonary fibrosis (FPF) is a fatal lung disease that is often not diagnosed until a significant portion of the lung function is lost. Median survival after diagnosis is 3 to 5 years. As treatment can only slow down lung function decline, early disease detection is essential to provide timely therapeutic support. As first-degree relatives of patients with FPF are at high risk of developing pulmonary fibrosis as well, a screening protocol has been put in place. However, the value of current screening parameters to detect early asymptomatic disease as well as the optimal interval between screening appointments are unknown. A prospective study into the prognostic value of these screening markers in the target population and the appropriate clinical setting is needed to develop an evidence-based screening protocol. There will be an emphasis on easily operable parameters that may allow for redirection of (part of the) screening activities to the general practice in the future.

Connect with a study center

  • St Antonius Hospital

    Nieuwegein, 3435CM
    Netherlands

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.